We are the “D” in
ADCs and PDCs.
A universal, light-activatable intracellular payload that adds an independent spatial control layer to molecular tumor targeting.
Our mission: make cancer a treatable disease — eliminating cancer cell by cell.
GenLumina is approaching a decisive preclinical value inflection. Over the past two years, we have advanced formulation and analytical work towards GLP-compatible development, established targeted conjugation in colorectal and breast cancer models, and progressed into in-vivo studies together with the Netherlands Cancer Institute (NKI). These studies are designed to establish the first integrated foundation of safety and efficacy before the more extensive regulatory-enabling programme required for a European CTA and a US IND.
Because our payload represents a new therapeutic modality designed to work with clinically validated antibodies and peptides, we believe pharmaceutical partnering offers the most capital-efficient route to patients. GenLumina is being built as a multi-partner platform company—closer in strategic model to companies such as Tubulis or CRISPR Therapeutics than to a single-asset biotech. The first pharmaceutical collaborations could materially increase the value of the broader platform. Thuja can help us reach that inflection through capital, transaction experience, an ADC and precision-oncology network, and the company-building expertise needed to secure and scale these partnerships.
Early-stage healthcare capital tied to a defined value inflection.
Thuja invests in early-stage biotech and medtech companies that require clinical validation, with reported tickets ranging from €250,000 to €10 million and patient impact as an explicit selection criterion.
Right stage
Preclinical oncology with a practical workplan to generate the animal evidence needed before clinical testing.
Right first ticket
The requested €500,000 lead commitment sits inside Thuja's reported investment range.
Platform upside
One controllable payload architecture can support multiple targeting ligands, indications and partnered programmes.
Patient impact
Local activation is designed to improve control over powerful cancer treatment and reduce exposure outside the treated area.
The VC we seek helps build the company.
GenLumina is deliberately looking for more than financing. We seek an active life-sciences investor who can help turn a scientific platform into a focused, partner-ready and scalable biotech company.
ADC & precision-oncology network
Relevant introductions to pharmaceutical companies, platform partners, experienced operators, clinical experts and specialist co-investors.
Market and partnering knowledge
Support in translating platform potential into partner propositions, indication choices, licensing routes and decision-ready commercial priorities.
Company building
Experience with governance, leadership recruitment, regulatory planning, programme management and the operating discipline required beyond the founder-led phase.
Syndication and follow-on
Help construct a milestone-based financing path and investor syndicate that can support GenLumina from preclinical validation towards scale-up and first-in-human development.
We are the controllable
“D” in ADCs and PDCs.
Molecular targeting
An antibody or peptide guides the conjugate towards selected tumor cells.
Cellular uptake
The conjugated payload is taken up and localises inside the targeted cells.
Light activation
Clinician-controlled light switches on the payload only in the illuminated treatment area.
Local cell killing
Activation creates a cytotoxic effect where targeting and illumination overlap.
Enough evidence to justify the next experiment.
The investment case is built around a clear de-risking step, not around claiming clinical proof too early.
- Patented light-activatable nanocluster payload technology
- Targeted peptide-conjugate activity in colorectal cancer models with LUMC
- Antibody-conjugate activity in HER2-positive breast cancer 3D spheroid models
- Approximately €1.1 million mobilised through loans, grants and research funding
- In-vivo efficacy and safety data with NKI and specialist research partners
- Selection and optimisation of the strongest conjugate programme
- A development package suitable for regulatory dialogue and pharmaceutical diligence
- A credible route towards first-in-human clinical testing
One platform.
Several financing paths.
GenLumina is built as an IP, licensing and R&D-support company. Programmes can be developed with pharmaceutical partners per target or indication without forcing every programme onto GenLumina's own balance sheet.
Institutional capital funds the platform inflection.
Lead investment advances core in-vivo evidence, strengthens the organisation and makes the platform investable and partner-ready. One standardised institutional financing structure preserves a clean, financeable cap table.
Partner and public capital can reduce follow-on dilution.
Pharmaceutical feasibility work, indication-specific project financing, licences, milestones and grants can supplement—or reduce—the equity required for later programmes. These routes create optionality; they do not compete with the first value-creating investment.
Lead €500k.
Staged to €5M.
The first commitment anchors a larger blended package and gives GenLumina the runway to progress evidence while negotiating public co-financing and pharmaceutical collaborations from a stronger position.
Institutional private anchor for the round
Complete the preclinical route towards first-in-human readiness
In-vivo package, lead programme and regulatory development plan
Could Thuja lead GenLumina's next value-creation step?
We invite Thuja to assess a €500,000 lead commitment, help shape the staged financing syndicate and use its life-sciences network and company-building experience to turn a controllable oncology payload into an in-vivo validated, partner-ready scale-up platform.